FDA Approves Pixclara for Glioma Imaging

Telix Pharmaceuticals Limited has achieved a significant milestone in the field of brain cancer diagnostics with the FDA approval of Pixclara®, the first FET-PET imaging drug for glioma. This approval addresses a critical unmet need in the medical community, enabling physicians to differentiate between recurrent or progressive glioma and treatment-related changes in both adult and pediatric patients.

Gliomas, the most common form of central nervous system cancer, account for approximately 30% of all brain and CNS tumors and 80% of all malignant brain tumors. In the United States, about 24,000 new glioma cases are diagnosed each year, highlighting the importance of accurate and reliable diagnostic tools.

Pixclara® is an intravenous positron emission tomography (PET) imaging drug that uses floretyrosine F18 to target membrane transport proteins known as L-type amino acid transporters 1 and 2 (LAT1 and LAT2). Once bound, energy emissions from the radioisotope can be detected by a PET scanner, allowing for precise imaging of gliomas. The drug is indicated for use in adults and pediatric patients 1 month of age and older.

Kevin Richardson, Chief Executive Officer of Telix Precision Medicine, expressed the significance of this approval: "FDA approval of Pixclara will enable broad access in the U.S. to FET-PET imaging, which is already recognized in international clinical practice guidelines. As the first FDA-approved PET imaging drug for glioma, Pixclara will provide physicians in the U.S. with more certainty in their diagnoses and greater confidence in their treatment planning for patients."

The approval of Pixclara® is a testament to Telix's commitment to advancing diagnostics and targeted radiopharmaceutical therapies. According to Kelly Sitkin, President and CEO of the American Brain Tumor Association, "The approval of Pixclara will advance glioma care by enabling more precise monitoring, complementing the role of MRI. We welcome the FDA's decision, which provides a pathway to access this technology in the U.S. and helps address a critical unmet need in brain cancer diagnostics."

Dr. Patrick Wen, E. Antonio Chiocca, MD, PhD, Family Endowed Chair in Neuro-Oncology at Mass General Brigham Cancer Institute, echoed the sentiment: "Having an FDA-approved FET-PET product with high diagnostic accuracy will make a significant, positive difference to the management of patients with gliomas. This is a very positive step forward for brain cancer imaging and treatment planning."

Pixclara® is part of Telix's precision diagnostics portfolio, which includes Illuccix® and Gozellix®. The company is also advancing its therapeutic pipeline, with TLX591-Tx, TLX101-Tx, and TLX250-Tx in pivotal-stage trials for prostate cancer, recurrent glioblastoma, and kidney cancer, respectively.

The approval of Pixclara® marks a significant step in the diagnosis and treatment of gliomas, providing a tool that can help improve patient outcomes and streamline clinical decision-making. With the growing burden of glioma cases in the U.S., this approval is expected to have a substantial impact on the medical community and patient care.